User login
RIO GRANDE, PUERTO RICO — Intranasal corticosteroids were no better than placebo for curing otitis media in children aged 4-11 years, based on data from a study of more than 200 children.
Dr. Ian Williamson of the University of Southampton (England) and his colleagues hypothesized that off-label intranasal corticosteroids might be effective against otitis media with effusion (OME), which is among the most common indications for surgery in young children in the United Kingdom.
The investigators randomized 217 children with OME diagnoses to receive 50 mcg of mometasone spray or a placebo spray in each nostril once daily for 3 months. The children were referred for the study from 99 family practices in the United Kingdom between 2004 and 2007.
The primary outcome was resolution of infection in at least one ear after 1 month, based on tympanometry data. Overall, the cure rate at 1 month was 41% among the 105 children who received corticosteroids and 45% among the 112 children who received the placebo spray. A secondary analysis at 3 months showed similar results, with cure rates of approximately 50% in each group, Dr. Williamson said at the annual meeting of the North American Primary Care Research Group.
Adverse events included nasal stinging, dry throat, cough, and nosebleed, but the incidence of these events was not significantly different.
Dr. Williamson stated that he had no financial conflicts to disclose.
RIO GRANDE, PUERTO RICO — Intranasal corticosteroids were no better than placebo for curing otitis media in children aged 4-11 years, based on data from a study of more than 200 children.
Dr. Ian Williamson of the University of Southampton (England) and his colleagues hypothesized that off-label intranasal corticosteroids might be effective against otitis media with effusion (OME), which is among the most common indications for surgery in young children in the United Kingdom.
The investigators randomized 217 children with OME diagnoses to receive 50 mcg of mometasone spray or a placebo spray in each nostril once daily for 3 months. The children were referred for the study from 99 family practices in the United Kingdom between 2004 and 2007.
The primary outcome was resolution of infection in at least one ear after 1 month, based on tympanometry data. Overall, the cure rate at 1 month was 41% among the 105 children who received corticosteroids and 45% among the 112 children who received the placebo spray. A secondary analysis at 3 months showed similar results, with cure rates of approximately 50% in each group, Dr. Williamson said at the annual meeting of the North American Primary Care Research Group.
Adverse events included nasal stinging, dry throat, cough, and nosebleed, but the incidence of these events was not significantly different.
Dr. Williamson stated that he had no financial conflicts to disclose.
RIO GRANDE, PUERTO RICO — Intranasal corticosteroids were no better than placebo for curing otitis media in children aged 4-11 years, based on data from a study of more than 200 children.
Dr. Ian Williamson of the University of Southampton (England) and his colleagues hypothesized that off-label intranasal corticosteroids might be effective against otitis media with effusion (OME), which is among the most common indications for surgery in young children in the United Kingdom.
The investigators randomized 217 children with OME diagnoses to receive 50 mcg of mometasone spray or a placebo spray in each nostril once daily for 3 months. The children were referred for the study from 99 family practices in the United Kingdom between 2004 and 2007.
The primary outcome was resolution of infection in at least one ear after 1 month, based on tympanometry data. Overall, the cure rate at 1 month was 41% among the 105 children who received corticosteroids and 45% among the 112 children who received the placebo spray. A secondary analysis at 3 months showed similar results, with cure rates of approximately 50% in each group, Dr. Williamson said at the annual meeting of the North American Primary Care Research Group.
Adverse events included nasal stinging, dry throat, cough, and nosebleed, but the incidence of these events was not significantly different.
Dr. Williamson stated that he had no financial conflicts to disclose.